JAMES SHEPPARD: Open Payments
NPI 1528075835 · THOMSON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$872 in 45 payments from 15 companies in 2025. Trend: 2023 $370 · 2024 $669 · 2025 $872
Food & beverage: $872
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $182 |
| AstraZeneca Pharmaceuticals LP | 1 | $149 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $92 |
| Lilly USA, LLC | 4 | $71 |
| Novo Nordisk Inc | 3 | $59 |
| Verona Pharma, Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| PFIZER INC. | 2 | $40 |
| UCB, Inc. | 1 | $33 |
Products named: AIRSUPRA, VRAYLAR, Kerendia, MOUNJARO, Ozempic, Ohtuvayre, REXULTI, CAPLYTA.
Industry payments across GA — which companies pay providers there.
